GE Healthcare has completed its acquisition of Orbotech Medical Solutions (OMS), a manufacturer of cadmium zinc telluride (CZT) detectors used in GE Healthcare's Alcyone nuclear medicine technology.
GE has received clearance from the U.S. Food and Drug Administration (FDA) for the use of CZT technology in the assessment and early detection of breast cancer in women who are at high risk for the disease.
The company's Discovery NM750b molecular breast imaging system utilizes the small field-of-view CZT gamma camera technology. The system has received 510(k) clearance and will be available in the U.S. in the second quarter.
